Omicron BA.1 and BA.2 Neutralizing Activity Following Pre-Exposure Prophylaxis with Tixagevimab plus Cilgavimab in Vaccinated Solid Organ Transplant RecipientsAndrew H. Karaba, William A. Werbel, Nicole Fortune et al.|medRxiv|2022Cited by 21
Neutralizing activity and 3-month durability of tixagevimab and cilgavimab prophylaxis against Omicron sublineages in transplant recipientsAndrew H. Karaba, William A. Werbel, Jake D. Kim et al.|American Journal of Transplantation|2023Cited by 12
Patient‐reported outcomes after Tixagevimab and Cilgavimab pre‐exposure prophylaxis among solid organ transplant recipients: Safety, effectiveness, and perceptions of riskJennifer L. Alejo, William A. Werbel, Jake D. Kim et al.|Clinical Transplantation|2023Cited by 10
Improved humoral immunogenicity with mRNA‐1273 versus BNT162b2 as third vaccine dose among solid organ transplant recipients seronegative after two BNT162b2 dosesAmy Chang, William A. Werbel, Teresa Po‐Yu Chiang et al.|Clinical Transplantation|2022Cited by 2
Incidence of SARS‐CoV‐2 infection among unvaccinated US adults during the Omicron waveJennifer L. Alejo, Dorry L. Segev, Teresa Po‐Yu Chiang et al.|Journal of Internal Medicine|2022Cited by 2